表紙
市場調查報告書

焦點市場分析:原發性硬化性膽管炎 (PSC)

Market Spotlight: Primary Sclerosing Cholangitis

出版商 Datamonitor Healthcare 商品編碼 603964
出版日期 內容資訊 英文 29 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:原發性硬化性膽管炎 (PSC) Market Spotlight: Primary Sclerosing Cholangitis
出版日期: 2020年04月27日內容資訊: 英文 29 Pages
簡介

全世界(30歲及以上)原發性硬化性膽管炎(PSC)患者的人數預計將從2017年的232,900人增加到2026年的270,300人。

本報告提供全球原發性硬化性膽管炎 (PSC) 治療藥市場相關調查分析,提供主要的開發平台藥物,最近的趨勢和分析師的見解,臨床實驗,成功的概率,今後趨勢與法規趨勢,專利資訊,10年的發病率預測,許可證·收購交易,收益預測相關的系統性資訊。

概要

要點

疾病的背景

  • 亞型

治療

流行病學

開發平台藥物

最近的趨勢和分析師的見解

  • Seladelpar
  • Cilofexor

今後趨勢

成功的概率

許可證·資產收購交易

臨床實驗形勢

  • 贊助商:各狀況
  • 贊助商:不同階段

參考文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0185608

Primary sclerosing cholangitis (PSC) is a progressive, rare, and chronic cholestatic liver disorder that is characterized by thickening, inflammation, and fibrosis of the bile ducts. Both intra- and extra-hepatic bile ducts are affected. This generally leads to cholestasis, liver cirrhosis, and eventually liver failure.

Key Takeaways:

  • Datamonitor Healthcare estimates that in 2019, there were 241,800 prevalent cases of primary sclerosing cholangitis (PSC) worldwide among adults aged 30 years and over, and forecasts that number to increase to 277,300 prevalent cases by 2028. The majority of industry-sponsored drugs in active clinical development for PSC are in Phase II, with only two drugs in Phase III. Therapies in the pipeline for PSC focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the oral route, with the remainder being tested in intravenous and subcutaneous formulations.
  • The only high-impact upcoming event for drugs in the PSC space is topline Phase II trial results for PLN-74809. The overall likelihood of approval of a Phase I autoimmune/immunology-other asset is 22.3%, and the average probability a drug advances from Phase III is 71.7%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.0 years in the overall autoimmune/immunology space.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for PSC have been in the early and midphases of development, with 80% of trials in Phase I-II, and only 20% in Phase III.
  • The US leads in terms of the number of PSC clinical trials globally, while the UK leads the major European markets.
  • Gilead Sciences has two completed trials and two ongoing trials in PSC.
  • Gilead Sciences has conducted two Phase II trials for PSC, as well as a single trial in Phase I and in Phase III.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

EPIDEMIOLOGY

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Seladelpar for PSC (November 25, 2019)
  • Cilofexor for PSC (November 9, 2018)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • BiomX Acquires PSC Targets From Japanese University

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of PSC, 2019-28
  • Figure 2: Overview of pipeline drugs for PSC in the US
  • Figure 3: Pipeline drugs for PSC, by company
  • Figure 4: Pipeline drugs for PSC, by drug type
  • Figure 5: Pipeline drugs for PSC, by classification
  • Figure 6: Cilofexor for PSC (November 9, 2018): Phase II - Without Cirrhosis
  • Figure 7: Key upcoming events in PSC
  • Figure 8: Probability of success in the PSC pipeline
  • Figure 9: Clinical trials in PSC
  • Figure 10: Top 10 drugs for clinical trials in PSC
  • Figure 11: Top 10 companies for clinical trials in PSC
  • Figure 12: Trial locations in PSC
  • Figure 13: PSC trials status
  • Figure 14: PSC trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of PSC, 2019-28
  • Table 2: Pipeline drugs for PSC in the US
  • Table 3: Seladelpar for PSC (November 25, 2019)
  • Table 4: Cilofexor for PSC (November 9, 2018)